Understanding vaccine safety information from the vaccine adverse event reporting system

被引:286
|
作者
Varricchio, F [1 ]
Iskander, J
Destefano, F
Ball, R
Pless, R
Braun, MM
Chen, RT
机构
[1] Food & Drug Adm, Ctr Biol Evaluat & Res, Off Biostat & Epidemiol, Div Epidemiol, Ottawa, ON, Canada
[2] CDCP, Natl Immunizat Program, Epidemiol & Surveillance Div, Immunizat Safety Branch, Ottawa, ON, Canada
[3] Hlth Canada, Ctr Infect Dis Prevent & Control, Immunizat & Resp Infect Div, Immunizat Safety Unit, Ottawa, ON K1A 0L2, Canada
关键词
adverse event; vaccine; vaccine adverse event reporting system (VAERS);
D O I
10.1097/00006454-200404000-00002
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
The Vaccine Adverse Event Reporting System (VAERS) is administered by the Food and Drug Administration and CDC and is a key component of postlicensure vaccine safety surveillance. Its primary function is to detect early warning signals and generate hypotheses about possible new vaccine adverse events or changes in frequency of known ones. VAERS is a passive surveillance system that relies on physicians and others to voluntarily submit reports of illness after vaccination. Manufacturers are required to report all adverse events of which they become aware. There are a number of well-described limitations of such reporting systems. These include, for example, variability in report quality, biased reporting, underreporting and the inability to determine whether a vaccine caused the adverse event in any individual report. Strengths of VAERS are that it is national in scope and timely. The information in VAERS reports is not necessarily complete nor is it verified systematically. Reports are classified as serious or nonserious based on regulatory criteria. Reports are coded by VAERS in a uniform way with a limited number of terms using a terminology called COSTART. Coding is useful for search purposes but is necessarily imprecise. VAERS is useful in detecting adverse events related to vaccines and most recently was used for enhanced reporting of adverse events in the national smallpox immunization campaign. VAERS data have always been publicly available. However, it is essential for users of VAERS data to be fully aware of the strengths and weaknesses of the system. VAERS data contain strong biases. Incidence rates and relative risks of specific adverse events cannot be calculated. Statistical significance tests and confidence intervals should be used with great caution and not routinely. Signals detected in VAERS should be subjected to further clinical and descriptive epidemiologic analysis. Confirmation in a controlled study is usually required. An understanding of the system's defined objectives and inherent drawbacks is vital to the effective use of VAERS data in vaccine safety investigations.
引用
收藏
页码:287 / 294
页数:8
相关论文
共 50 条
  • [21] Tinnitus after COVID-19 vaccination: Findings from the vaccine adverse event reporting system and the vaccine safety datalink
    Yih, W. Katherine
    Duffy, Jonathan
    Su, John R.
    Bazel, Samaneh
    Fireman, Bruce
    Hurley, Laura
    Maro, Judith C.
    Marquez, Paige
    Moro, Pedro
    Nair, Narayan
    Nelson, Jennifer
    Smith, Ning
    Sundaram, Maria
    Vasquez-Benitez, Gabriela
    Weintraub, Eric
    Xu, Stanley
    Shimabukuro, Tom
    AMERICAN JOURNAL OF OTOLARYNGOLOGY, 2024, 45 (06)
  • [22] Safety of meningococcal polysaccharide-protein conjugate vaccine in pregnancy: a review of the Vaccine Adverse Event Reporting System
    Zheteyeva, Yenlik
    Moro, Pedro L.
    Yue, Xin
    Broder, Karen
    AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY, 2013, 208 (06) : 478.e1 - 478.e6
  • [23] Application of Information Retrieval Approaches to Case Classification in the Vaccine Adverse Event Reporting System
    Botsis, Taxiarchis
    Woo, Emily Jane
    Ball, Robert
    DRUG SAFETY, 2013, 36 (07) : 573 - 582
  • [24] Application of Information Retrieval Approaches to Case Classification in the Vaccine Adverse Event Reporting System
    Taxiarchis Botsis
    Emily Jane Woo
    Robert Ball
    Drug Safety, 2013, 36 : 573 - 582
  • [25] Internet-Based Reporting to the Vaccine Adverse Event Reporting System: A More Timely and Complete Way for Providers to Support Vaccine Safety
    Haber, Penina
    Iskander, John
    Walton, Kimp
    Campbell, Scott R.
    Kohl, Katrin S.
    PEDIATRICS, 2011, 127 : S39 - S44
  • [26] Vaccine adverse event text mining system for extracting features from vaccine safety reports
    Botsis, Taxiarchis
    Buttolph, Thomas
    Nguyen, Michael D.
    Winiecki, Scott
    Woo, Emily Jane
    Ball, Robert
    JOURNAL OF THE AMERICAN MEDICAL INFORMATICS ASSOCIATION, 2012, 19 (06) : 1011 - 1018
  • [27] Safety surveillance of meningococcal group B vaccine (Bexsero®), Vaccine Adverse Event Reporting System, 2015-2018
    Perez-Vilar, Silvia
    Dores, Graca M.
    Marquez, Paige L.
    Ng, Carmen S.
    Cano, Maria, V
    Rastogi, Anuja
    Lee, Lucia
    Su, John R.
    Duffy, Jonathan
    VACCINE, 2022, 40 (02) : 247 - 254
  • [28] Can the vaccine adverse event reporting system be used to increase vaccine acceptance and trust?
    Scherer, Laura D.
    Shaffer, Victoria A.
    Patel, Niraj
    Zikmund-Fisher, Brian J.
    VACCINE, 2016, 34 (21) : 2424 - 2429
  • [29] Safety of bivalent human papillomavirus vaccine in the US vaccine adverse event reporting system (VAERS), 2009-2017
    Suragh, Tiffany A.
    Lewis, Paige
    Arana, Jorge
    Mba-Jonas, Adamma
    Li, Rongxia
    Stewart, Brock
    Shimabukuro, Tom T.
    Cano, Maria
    BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2018, 84 (12) : 2928 - 2932
  • [30] Safety Surveillance of Bivalent Meningococcal Group B Vaccine, Vaccine Adverse Event Reporting System, 2014-2018
    Duffy, Jonathan
    Marquez, Paige
    Dores, Graca M.
    Ng, Carmen
    Su, John
    Cano, Maria
    Perez-Vilar, Silvia
    OPEN FORUM INFECTIOUS DISEASES, 2020, 7 (12):